The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives

Henrotin, Yves; Sanchez, Christelle; Reginster, Jean-Yves

doi:10.1517/13543776.12.1.29

Request a copy

Article (Scientific journals)

The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives

Henrotin, Yves; Sanchez, Christelle; Reginster, Jean-Yves

2002 • In Expert Opinion on Therapeutic Patents, 12 (1), p. 29-43

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/1513

DOI
10.1517/13543776.12.1.29

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2002MMPs.pdf

Publisher postprint (230.69 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

cartilage; inhibitors; metalloproteinases; osteoarthritis

Abstract :

[en] The objective of this paper is to analyse the potential therapeutic action of MMP inhibitors in the management of osteoarthritis (OA), based on a critical review of the literature. The role played by metalloproteinases (MPs) in the pathophysiology of osteoarthritis is discussed, as well as their regulation by tissular inhibitors, activators and cytokines. The evidences that commonly used drugs for treating osteoarthritis are also active on MPs synthesis is also reported. Finally, this paper provides an analysis of the recent patents published with promising therapeutic potential and gives new perspectives for anti-MPs therapy.

Disciplines :

Pharmacy, pharmacology & toxicology
Rheumatology

Author, co-author :

Henrotin, Yves ; Université de Liège - ULiège > Unité de recherche sur l'os et le cartillage (U.R.O.C.)

Sanchez, Christelle ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives

Publication date :

January 2002

Journal title :

Expert Opinion on Therapeutic Patents

ISSN :

1354-3776

eISSN :

1744-7674

Publisher :

Ashley Publications Ltd, London, United Kingdom

Volume :

Issue :

Pages :

29-43

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 November 2008

Statistics

Number of views

102 (8 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Thonar E.J.M.A., Masuda K., Manicourt D., Kuettner K.E. (1999) Structure and function of normal human adult articular cartilage. Osteoarthritis: Clinical and Experimental Aspects , Reginster J-Y, Martel-Pelletier J, Pelletier J-P, Henrotin Y (Eds). Springer, Berlin Heidelberg; 1-19.
Martel-Pelletier J., Di Battista J., Lajeunesse D. (1999) Biochemical factors in joint articular tissue degradation. Osteoarthritis: Clinical and Experimental Aspects , Reginster J-Y, Martel-Pelletier J, Pelletier J-P, Henrotin Y (Eds). Springer, Berlin Heidelberg; 156-188.
Goldring M.B. (2000) The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 9:1916-1927.
Naito K., Takahashi M., Kushida K. (1999) Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: Comparison with generalized osteoarthritis. Rheumatology 38:510-515.
Tetlow L.C., Adlam D.J., Woolley D.E. (2001) Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis Rheum. 44(3):585-594.
Bluteau G., Conrozier T., Mathieu P., Vignon E., Herbage D., Mallein-Gerin F. (2001) Matrix metalloproteinase-1, -3, -13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis. Biochim. Biophys. Acta. 1526:147-158.
Tetlow L.C., Wooley D.E. (2001) Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cart. 9:423-431.
Walter H., Kawashim A., Nebelung W., Neumann W., Roessner A. (1998) Immunohistochemical analysis of several proteolytic enzymes as parameters of cartilage degradation. Pathol. Res. Pract. 194(2):73-81.
Milner J.M., Elliott S.F., Cawston T.E. (2001) Activation of procollagenases is a key control point in cartilage collagen degradation. Arthritis Rheum. 44(9):2084-2096.
Murphy G., Cockett M.I., Stephens P.E., Smith B.J., Doherty A.J. (1987) Stromelysin is an activator of procollagenase: A study with natural and recombinant enzymes. Biochem. J. 248:265-268.
Knauper V., Wilhelm S.M., Seperack P.K. (1993) Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem. J. 295:581-586.
He C., Wilhem S.M., Pentland A.P. (1989) Tissue cooperation in a proteolytic cascade activating human intertitial collagenase. Proc. Natl. Acad. Sci. USA 86:2632-2636.
Eeckout Y., Vaes G. (1977) Further studies on the activation of procollagenase, the latent precursor of bone collagenase: Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem. J. 166:21-31.
Treadwell B.V., Pavia M., Towle C.A., Cooley V.J., Mankin H.J. (1991) Cartilage synthesizes the serine proteinase inhibitor PAI-1: Support for the involvement of serine proteases in cartilage remodeling. J. Orthop. Res. 9:309-316.
Belcher C., Fawthrop F., Bunning R., Doherty M. (1996) Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann. Rheum. Dis. 55:230-236.
Martel-Pelletier J., Faure M.P., McCollum R., Mineau F., Cloutier J.M., Pelletier J.P. (1991) Plasmin, Plasminogen activators and inhibitors in human osteoarthritic cartilage. J. Rheumatol. 18:1863-1871.
Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., Woessner J.F. (1989) Evidence for metalloproteinases and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest. 84:678-685.
Chubinskaya S., Kuettner K.E., Cole A.A. (1999) Expression of matrix metalloproteinases in normal and damaged articular cartilage from human knee and ankle joints. Lab. Invest. 79:1669-1699.
Lark M.W., Bayne E.K., Flanagan J. (1997) Aggrecan degradation in human cartilage. J. Clin. Invest. 100:93-106.
Billinghurst R.C., Dahlberg L., Ionescu M. (1997) Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 99:1534-1545.
Bayliss M.T., Hutton S., Hayward J., Maciewicz R.A. (2001) Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human cartilage: The influence of age topography and zone of tissue. Osteoarthritis Cart. 9:553-560.
Manicourt D., Fujimoto N., Obata K., Thonar E.J.M. (1994) Serum levels of collagenase, stromelysin-1, and TIMP-1. Arthritis Rheum. 37(12):1774-1783.
Lohmander S., Hoerrner L.A., Lark M.W. (1993) Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 36(2):181-189.
Kozaci L.D., Buttle D.J., Hollander A.P. (1997) Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum. 40:164-174.
Chambers M.G., Cox L., Chong L. (2001) Matrix metalloproteinases and aggrecanases cleavage aggrecan in different zones of normal cartilage but cofocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum. 44:1544-1565.
Martel-Pelletier J., Mc Collum R., Fujimoto N., Obata K., Cloutier J.M., Pelletier J.P. (1994) Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab. Invest. 70(6):807-831.
Okada Y., Shimnei M., Tanaka O. (1992) Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab. Invest. 66(6):680-690.
Dahlberg L., Billinghurst R.C., Manner P. (2000) Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. 43(3):673-682.
Mitchell P.G., Magna H.A., Reeves L.M. (1996) Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Invest. 97:761-768.
Catterrall J.B., Carrere S., Koshy P.J.T. (2001) Synergic induction of matrix metalloproteinase 1 by interleukin-1α and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis Rheum. 44(10):2296-2310.
Reboul P., Pelletier J.P., Tardiff G., Cloutier J.M., Martel-Pelletier J. (1996) The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: A role in osteoarthritis. J. Clin. Invest. 97:2011-2019.
Fernandes J.C., Martel-Pelletier J., Lascau-Coman V. (1998) Collagenase-1 and collagenase-3 synthesis in normal and early experimental osteoarthritic canine cartilage: An immunohistochemical study. J. Rheumatol. 25:1585-1594.
Shlopov B.I., Smith G.N., Cole A.A., Hasty K.A. (1999) Differential patterns of response to doxycycline and transforming growth factor β1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum. 42(4):719-727.
Tardif G., Pelletier J.-P., Dupuis M., Geng C., Cloutier J.-M., Martel-Pelletier J. (1999) Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells. Arthritis Rheum. 42(6):1147-1158.
Mengshol J.A., Vincenti M.P., Coon C.I., Barchowsky A., Brinckerhoff C.E. (2000) Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-jun n-terminal kinase, and nuclear factor kB. Arthritis Rheum. 43(4):801-811.
Sandy J.D., Flannery C.R., Neame P.J., Lohmander S.L. (1992) The structure of aggrecan fragments in human osteoarthritic synovial fluid: Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the glu373-ala374 bond of the interglobular domain. J. Clin. Invest. 89:1512-1516.
Tang B.L. (2001) ADAMTS: A novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 33(1):33-44.
Caterson B., Flannery C.R., Hughes C.E., Little C.B. (2000) Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 19(4):333-344.
Tortorella M., Pratta M., Liu R.Q. (2000) The thrombospondin motif of aggrecanase 1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J. Biol. Chem. 275:25791-25797.
Sugimoto K., Takahashi M., Yamamoto Y., Shimada K., Tanzawa K. (1999) Identification of aggrecanase activity in medium of cartilage culture. J. Biochem. 126:449-455.
Vankemmelbeke M., Holen I., Wilson A.G. (2001) Expression and activity of ADAMTS-5 in synovium. Eur. J. Biochem. 268:1259-1268.
Tortorella M.D., Malfait A.-M., Deccico C., Arner E. (2001) The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cart. 9:539-552.
Kashiwagi M., Tortorella M., Nagase H., Brew K. (2001) TIMP-3 is a potent inhibitor of aggrecanase-1 (ADAM-TS4) and aggrecanase-2 (ADAM-TS5). J. Biol. Chem. 276(16):12501-12504.
Kuno K., Okada Y., Kawashima H. (2000) ADAM-TS1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett. 478(3):241-245.
Flannery C.R., Little C.B., Hughes C.E., Caterson B. (1999) Expression of ADAMTS homologue in articular cartilage. Biochem. Biophys. Res. Commun. 260:318-322.
Abbaszade I., Liu R.-Q., Yang F. (1999) Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J. Biol. Chem. 274(33):23443-23450.
Buttner F.H., Chubinskaya S., Margerie D. (1997) Expression of membrane type 1 matrix metalloproteinase in human articular cartilage. Arthritis Rheum. 40:704-709.
Ohuchi E., Imai K., Fujii Y., Sato H., Seiki M., Okada Y. (1997) Membrane type 1 matrix metalloproteinase digest interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 272:2446-2451.
Imai K., Ohta S., Matsumoto T. (1997) Expression of membrane type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. Am. J. Path. 151:153-159.
Böhm B.B., Aigner T., Gehritz A., Blobel C.P., Kalden J.R., Burkhardt H. (1999) Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritis Rheum. 42(9):1946-1950.
McKie N., Edwards T., Dallas D.J. (1997) Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochem. Biophys. Res. Commun. 230:335-339.
Black R.A., Rauch C.T., Kozlosky C.J. (1997) A metalloproteinase desintegrin that releases tumour-necrosis factor α from cells. Nature 385:729-733.
Patel I.R., Attur M.G., Patel R.N. (1998) TNF-α convertase enzyme from human arthritis-affected cartilage: Isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-α. J. Immunol. 160:4570-4579.
Chubinskaya S., Mikhail R., Deutsch A., Tindal M.H. (2001) ADAM-10 protein is present in human articular cartilage primarily in the membrane form and is upregulated in osteoarthritis and in response to IL-1α in bovine nasal cartilage. J. Histochem. Cytochem. 49:1165-1176.
Knauper V., Lopez-Otin C., Smith B., Knight G., Murphy G. (1996) Biochemical characterization of human collagenase-3. J. Biol. Chem. 271:1544-1550.
Sato H., Takino T., Okada Y. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65.
Takino T., Sato H., Shinagawa A., Seiki M. (1995) Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library: MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 270:23013-23020.
Matsumoto S.I., Katoh M., Saito S., Watanabe T., Masuho Y. (1997) Identification of soluble type of membrane-type matrix metalloproteinases-3 formed by alternatively spliced mRNA. Biochim. Biophys. Acta. 1354:159-170.
Pei D. (1999) Identification and characterization of the fifth membrane-type metalloproteinases MT5-MMP. J. Biol. Chem. 274:8925-8932.
Velasco G., Cal S., Merlos-Suarez A. (2000) Human MT6-matrix metalloproteinase: Identification, progelatinase A activation and expression in brain tumors. Cancer Res. 60:877-882.
Pei D., Weiss S.F. (1995) Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375:244-247.
Werb Z., Mainardi C.L., Vater C.A. (1977) Endogenous activation of latent collagenase by rheumatoid synovial cells: Evidence for a role of plasminogen activator. N. Engl. J. Med. 296:1017-1023.
Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer 72:1-22.
Schwab W., Gavlik J.M., Beichler T. (2001) Expression of the urokinase-type plasminogen activator receptor in human articular chondrocytes: Association with caveolin and β 1-integrin. Histochem. Cell. Biol. 115:317-323.
Del Rosso M., Fibbi G., Pucci M., Cerenic M.M. (1998) Antisense oligonucleotides against the urokinase receptor: A therapeutic strategy for of cell invasion in rheumatoid arthritis and cancer. Clin. Exp. Rheumatol. 16(4):389-393.
Fibbi G., Pucci M., Serni U., Cerenic M.M., Del Rosso M. (1998) Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro. Proc. Assoc. Am. Physicians 110(4):340-350.
Pollanen J., Stephens R.W., Vaheri A. (1991) Direct plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res. 57:273-328.
Campbell I.K., Last K., Novak U., Lund L.R., Hamilton J.A. (1991) Recombinant human interleukin-1 inhibits plasminogen activator inhibitors-1 (PAI-1) production by human articular cartilage and chondrocytes. Biochem. Biophys. Res. Commun. 174:251-257.
Lang A., Horler D., Baici A. (2000) The relative importance of cysteine peptidases in osteoarthritis. J. Rheumatol. 27:1970-1979.
Martel-Pelletier J., Cloutier J.M., Pelletier J.P. (1990) Cathepsin B and cysteine protease inhibitors in human OA: Effect of intra-articular steroid injections. J. Orthop. Res. 8:336-344.
Keyszer G., Redlich A., Häupl T. (1998) Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 41(8):1378-1387.
Dodds R.A., Connors J.E., Drake F.H., Gowen M. (1999) Expression of cathepsin K messenger RNA in giants cells and their precursors in human osteoarthritis synovial tissues. Arthritis Rheum. 42(8):1588-1593.
Kostoulas G., Lang A., Nagase H., Baici A. (1999) Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett. 455:286-290.
Hansen T., Petrow P.K., Gaumann A. (2000) Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium. J. Rheumatol. 27(4):859-865.
Lenarcic B., Gabrijelcic D., Rozman B., Drobnic-Kosorok M., Turk V. (1988) Human cathepsin B and cysteine proteinases inhibitors (CPIs) in inflammatory and metabolic disease. Biol. Chem. Hoppe. Seyler. 369:257-261.
Hernandez-Barrantes S., Toth M., Bernardo M.M. (2000) Binding of active (57 Kda) membrane type-1-matrix metalloproteinase (MTI-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem. 275:12080-12089.
Apparailly F., Noel D., Millet V. (2001) Paradoxal effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis Rheum. 44:1444-1454.
(2000) Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. Arthritis Rheum. , American College of Rheumatology Subcommittee on Osteoarthritis Guidelines; 43(9):1905-1915.
(1996) Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann. Rheum. Dis. , Group for Respect of Ethics and Excellence in Science (Gress): Osteoarthritis Section; 55:552-557.
Reginster J.Y., Deroisy R., Rovati L. (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. The Lancet 357:251-256.
Pavelka K., Gatterova J., Olejarova M. (2000) Glucosamine sulfate decreases progression of knee osteoarthritis in a long-term, randomized, placebo-controlled, independent, confirmatory trial. Arthritis Rheum. 43(SUPPL. 9).
Pelletier J.P., Yaron M., Haraoui B. (2000) Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo controlled trial. The diacerein study group. Arthritis Rheum. 43:2339-2348.
Appelboom T., Schermans J., Verbruggen G., Henrotin Y., Reginster J.-Y. (2001) Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. Scand. J. Rheumatol. 30:242-247.
Jimenez S.A., Dodge G.R. (1997) The effects of glucosamine sulfate (GS04) on human chondrocyte gene expression. Osteoarthritis Cart. 5 SA:72.
Sandy J.D., Gamett D., Thompson V., Verscharen C. (1998) Chondrocyte-mediated catabolism of aggrecan: Aggrecanase-dependent cleavage induced by interleukin-1 and retinoic acid can be inhibited by glucosamine. Biochem. J. 335:59-65.
Boumediene K., Felisaz N., Bogdanowicz P., Galera P., Guillou B., Pujol J.-P. (1999) Avocado/soya unsaponifiables enhance the expression of transforming growth factor β1 and β2 in cultured articular chondrocytes. Arthritis Rheum. 42(1):148-156.
Henrotin Y., Labasse A.H., Jaspar J.-M. (1998) Effects of three avocado/soybean unsaponifiable mistures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin. Rheumatol. 17:31-39.
Henrotin Y., Sanchez C., Debergh M., Piccardie N., Guillou B., Reginster J.-Y. (2001) Long-term effects of avocado/soybean unsaponifiable on human chondrocytes metabolism. Osteoarthritis Cart. 9(SUPPL. B).
Tamura A., Kosaka N., Ishiwa J., Sato T., Nagase H., Ito A. (2001) Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -2, -9 and -13 and upregulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular. Osteoarthritis Cart. 9:257-263.
Carney S.L. (1996) Effect of diacetyl rhein on the development of experimental osteoarthritis. A biochemical investigation. Osteoarthritis Cart. 4:251-261.
Hwa S.-Y., Burkhardt D., Little C., Ghosh P. (2001) The effects of orally administrated diacerein on cartilage and subchondral bone in ovine model of osteoarthritis. J. Rheumatol. 28:825-843.
Pujol J.-P., Felisaz N., Boumediene K. (2000) Effects of diacerein on biosynthesis activities of chondrocytes in culture. Biorheology 37:177-184.
Cake M.A., Reas R.A., Guillou B., Ghosh P. (2000) Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cart. 8:404-411.
Yip D., Ahmad A., Karapetis C.S., Hawkins C.A., Harper P.G. (1999) Matrix metalloproteinase inhibitors: Applications in oncology. Investig. New Drugs 17:387-399.
Shaw T., Nixon J.S., Bottomley K.M. (2000) Metalloproteinase inhibitors: New opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Expert Opin. Investig. Drugs 9(7):1469-1478.
Brown P. (2000) Ongoing trial with matrix metalloproteinase inhibitors. Expert Opin. Investig. Drugs 9(9):2167-2177.
Skiles J.W., Gonnella N.C., Jeng A.Y. (2201) The Design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 8(4):425-474.
Shah A., Woodruff M., Agarwal V., Liu P., Sundaresan P. (2001) Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis. J. Clin. Pharmacol. 41:330-339.
Leff R.L. (1999) Clinical trials of a stromelysin inhibitor. Osteoarthritis, matrix metalloproteinase inhibition, cartilage loss, surrogate markers, and clinical implications. Ann. NY Acad. Sci. 878:201-207.
Billinghurst R.C., O'Brien K., Poole A.R., McIllwraith C.W. (1999) Inhibitions of articular cartilage degradation in culture by a novel nonpeptide matrix metalloproteinase inhibitor. Ann. NY Acad. Sci. 878:594-597.
Chau T., Jolly G., Plym J.M. (1998) Inhibition of of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor, BAY 12-9566. Arthritis Rheum. 41(SUPPL. 9).
Leff R.A., Elias I., Ionescu M., Reiner A., Poole A.I. (2000) Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566. A novel matrix metalloproteinase inhibitor. Arthritis Rheum. 42(SUPPL. 9).
Wang M., Liu Y.E., Greene G. Oncogene 1997, 14:2767.
Lollini L., Harler J., Eugui E. (1997) Disease modification by RS-130,830, a collagenase selective inhibitor in experimental osteoarthritis (OA). Arthritis Rheum. 40(SUPPL. 87):341.
Lewis E.J., Bishop J., Bottomley K.M.K. (1997) RO 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. J. Pharmacol. 121:540-546.
Brewster M., Lewis E.J., Wilson K.L., Greenham A.K., Bottomley K.M.K. (1998) Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the str/ort mouse model of osteoarthritis. Arthritis Rheum. 41(9):1639-1644.
Wood N., Aitken M., Harris S., Kitchener S., McClelland G., Sharp S. (1996) The tolerability and pharmacokinetics of the cartilage protective agent (RO 32-3555) in healthy male volunteers. Brit. J. Clin. Pharm. 42:676-677.
(2000) Roche puts arthritis drug on hold. Scrip 2528:20.
Natchus M.G., Bookland R.G., De B. (2000) Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J. Med. Chem. 43(26):4948-4963.
Amin A.R., Patel I.R., Attur M. (1997) A novel snake venom-like protease (SVP) from human arthritis-affected cartilage has properties of TNF-α convertase regulation in arthritis-affected cartilage. Arthritis Rheum. 40(SUPPL.).
Farahat N.M., Yanni G., Poston R., Panayi G.S. (1993) Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. 52:870-875.
Jouglin M., Robert C., Valette J.P., Gavard F., Quintin-Colonna F., Denoix J.M. (2000) Metalloproteinases and tumor necrosis factor-α activities in synovial fluids of horse and correlation with articular cartilage alterations. Vet. Res. 31(5):507-515.
Moo V., Sieper J., Herzog V., Muller B.M. (2001) Regulation of expression of cytokines and growth factors in osteoarthritic cartilage explants. Clin. Rheumatol. 20(5):353-358.
Caron J.P., Fernandes J.C., Martel-Pelletier J. (1996) Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: Suppression of collagenase expression. Arthritis Rheum. 39:1535-1544.
Van de Loo F.A., Joosten L.A., Van Lent P.L., Arntz O.J., Van den Berg W.B. (1995) Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen-and zymosan-induced arthritis. Arthritis Rheum. 38:164-172.
Plows D., Probert L., Georgopoulos S., Alexopoulou L., Kollias G. (1995) The role of tumour necrosis factor (TNF) in arthritis: Studies in transgenic mice. Rheumatol. Eur. 2(SUPPL.):51-54.
Chikanza I.C., Roux-Lombard P., Dayer J.M., Panayi G.S. (1993) Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin. Exp. Immunol. 92:19-22.
Westacott C.I., Barakat A.F., Wood L. (2000) Tumor necrosis factor α can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis Cart. 8(3):313-321.
Elliott M.J., Maini R.L., Feldmann M. (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrasis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110.
Moreland L.W., Baumgartner S.W., Schiff M.H. (1997) Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337:141-147.
Conway J.G., Andrews R., Beaudet B. (2001) Inhibition of tumor necrosis factor α (TNFα) production and arthritis in the rat by GW3333, a dual inhibitor of TNFα-converting enzyme and matrix metalloproteinases. Pharmacol. Exp. Ther. 3:900-908.